Effect of Bevacizumab in Macular Drusen-A Case Report
0
Citation
0
Reference
20
Related Paper
Abstract:
Purpose: To report the effect of intravitreal injection of bevacizumab in macular drusen. Methods: A case report. Results: A 74 yeas old male patient presented to our clinic with the complaint of decreased visual acuity (OS) for several years. An age-related macular degeneration with macular drusen (OS) was noted during his fundus examination and fluorescein angiography (FAG). He received three intravitreal injection of bevacizumab (2.5 mg/0.1ml) consecutively. Post injection best-corrected visual acuity (BCVA), fundus exam, and FAG findings were carefully followed. Three months after intravitreal injection of bevacizumab, the fundus exam and FAG demonstrated regression of macular drusen with improvement of visual acuity. Conclusion: Intravitreal injection of bevacizumab regress the macular drusen and improved patient's vision. Therefore, intravitreal injection of bevacizumab may be useful for the treatment of macular drusen.Keywords:
Drusen
Fundus (uterus)
Microperimetry
Cite
Citations (27)
Cite
Citations (7)
Cite
Citations (33)
Fundus (uterus)
Cite
Citations (44)
Cite
Citations (0)
Purpose: The purpose of this study was to report a case of macular hole formation in a patient with myopic choroidal neovascularization (CNV), who was administered intravitreal bevacizumab. Methods: A 55-year-old woman with high myopia presented with a sudden decrease in vision in her right eye. Optical coherence tomography imaging showed subfoveal type 2 CNV and a preretinal structure with vitreomacular traction. The patient received intravitreal bevacizumab treatment for the CNV. Results: Four weeks after the second intravitreal bevacizumab injection, regression of CNV and formation of a macular hole were confirmed from the findings of the optical coherence tomography image. The patient was followed up without further treatment. Six months after the second intravitreal bevacizumab injection, the macular hole closed spontaneously, and visual acuity improved in her right eye. Conclusion: Intravitreal bevacizumab is a powerful modality in the management of myopic CNV; however, the possibility of infrequent complication should be considered.
Cite
Citations (15)
To determine the visual and anatomic outcome of intravitreal Bevacizumab injection in the treatment of neovascular age-related macular degeneration (AMD).Quasi-experimental study.Layton Rahmatulla Benevolent Trust Eye Hospital (LRBT), Lahore, from January to July 2010.Patients who received, one or more intravitreal Bevacizumab injections (1.25 mg per 0.05 ml) for exudative AMD were included in the study. Outcome measures included standardized visual acuity, optical coherence tomography (OCT), macular thickness, intraocular pressure, and blood pressure at 24 or more weeks follow-up. Descriptive statistics were obtained.Fifty eyes with exudative AMD were observed for six months. The mean VA improved from 0.21 ± 0.11 before injections to 0.43 ± 0.11 after injections at six months. Overall, mean OCT macular thickness decreased by 99 micron at last follow-up. At last follow-up, all eyes received an average of 3.28 ± 0.85 injections. There was no incidence of severe vision loss or adverse effects like endophthalmitis or retinal detachment.Intravitreal Bevacizumab has the potential for improvement of vision in exudative AMD for at least 6 months.
Cite
Citations (1)
We report on the combined application of intravitreal bevacizumab and triamcinolone acetonide for treatment of exudative age-related macular degeneration (AMD). The clinical interventional case-series study included 16 patients (16 eyes) with exudative AMD who had previously received 3.5±1.8 mono-injections of bevacizumab (1.5mg) without significant improvement in visual acuity (VA) or reduction in macular exudation. All patients underwent a combined intravitreal injection of bevacizumab (1.5mg) and triamcinolone acetonide (about 20mg). Main outcome measures were VA and macular thickness as determined by optical coherence tomography. All patients were re-examined at 2-3months after the intervention.Visual acuity improved significantly (p=0.03) from 0.80±0.40 logMAR prior to the combined injection to 0.65±0.42 logMAR at 3 months after the injection. An improvement of ≥1Snellen line was found in eight subjects, an increase of ≥2lines in five subjects, and an improvement of ≥3lines in two subjects. One patient lost 1line and one patient lost 3lines. Central retinal thickness decreased significantly from 272±62μm to 220±47μm (p=0.03). At the 6-month follow-up examination, central retinal thickness had increased again to 319±142μm, which was not significantly (p=0.30) different from baseline measurements.The combined intravitreal application of bevacizumab and triamcinolone may temporarily be helpful in the treatment of exudative AMD if previous intravitreal bevacizumab mono-injections have failed to improve vision and reduce macular oedema.
Acetonide
Cite
Citations (20)
To evaluate the safety and efficacy of intravitreal Bevacizumab in treatment of non-ischemic macular edema secondary to retinal vein obstruction (RVO).A 2-year-retrospective study was performed on 26 patients hospitalized for non-ischemic macular edema secondary to RVO. All the patients underwent a complete ophthalmologic exam, with best corrected visual acuity (BCVA) testing, fundus photography, fluorescein angiography (FA) and macular thickness measurement by optical coherence tomography (OCT). Reevaluation was performed monthly for VA, OCT, and ophthalmoscopy and, at every 3 months, by FA. A standard protocol of 0.05 ml intravitreal Bevacizumab injection was applied. Further administrations were performed according to clinical evolution.The medium follow-up period was of 9,7 months (6-20 months). There were no significant complications following the procedure. The number of intravitreal Bevacizumab injections varied from 2-5/ patient. All the patients experienced an improvement in VA and a significant regression of macular edema. The smallest number of intravitreal Bevacizumab injections and the best visual prognosis were observed in cases with branch retinal vein obstruction (BRVO) and early presentation (p<0.05).As a pathogenic therapy, intravitreal Bevacizumab is a safe, repeatable procedure and it may be considered an effective and lasting treatment for non-ischemic macular edema secondary to RVO. Intravitreal Bevacizumab should be included in the therapeutic protocol of RVO, both for early and delayed presentations. Abbreviations: RVO = retinal vein obstruction, BRVO = branch retinal vein obstruction, CRVO = central retinal branch obstruction, BCVA = best corrected visual acuity, FA = fluorescein angiography, OCT = optical coherence tomography.
Retinal Vein
Cite
Citations (3)
Cite
Citations (8)